Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
This virtual event on March 29, 2023 featured presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, detailed the initial pipeline targets, and provided guidance on the advancement of programs toward the clinic. ProQR also reported its 2022 year-end financials and the extension of its cash runway guidance.
This is Gerard Platenburg's presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.
Development of RNA Base Editing Technologies for Precision Medicines with Axiomer® and Trident® presented at TIDES USA 2022 by Gerard Platenburg - ProQR Therapeutics.
Axiomer® platform applicability and potential in therapeutically relevant models for targeted RNA editing presented at TIDES EU 2018 by Antti Aalto - ProQR Therapeutics